Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-1 adrenergic receptors (α1-ARs) are a class of G protein-coupled receptors (GPCRs) primarily located on vascular smooth muscle, where they play a critical role in regulating systemic vascular resistance and blood pressure [1, 2, 5]. Upon activation by endogenous catecholamines like norepinephrine and epinephrine, these receptors couple with Gq proteins to trigger a signaling cascade involving phospholipase C, which increases intracellular calcium levels and leads to smooth muscle contraction, resulting in vasoconstriction [2, 6, 13]. The α1-AR family consists of three highly homologous subtypes—α1A, α1B, and α1D—each with varying distributions across different vascular beds and tissues [3, 4, 5]. In clinical practice, α1-AR agonists such as phenylephrine and norepinephrine are utilized to treat hypotensive states and shock by inducing vasoconstriction [7, 15, 17]. Conversely, α1-AR antagonists like prazosin, doxazosin, and tamsulosin are employed to manage hypertension and benign prostatic hyperplasia (BPH) by promoting vasodilation and relaxing prostatic smooth muscle [8, 14, 16]. Therapeutic targeting of these receptors requires careful management of side effects, most notably orthostatic hypotension and reflex tachycardia, which result from the potent effects of these drugs on vascular tone [8, 10, 16].
Alpha-1 adrenergic receptors are Gq protein-coupled receptors [5, 6]. Activation by agonists leads to the activation of phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG) [2, 6, 13]. IP3 triggers the release of calcium from the sarcoplasmic reticulum, while DAG activates protein kinase C (PKC) [2, 6]. The resulting increase in intracellular calcium concentration promotes the formation of the calcium-calmodulin complex, activating myosin light chain kinase (MLCK) and leading to smooth muscle contraction and vasoconstriction [2, 6, 10].
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-1 adrenergic receptor (α1-AR) (α1-AR).